Seeking Alpha
 

Pfizer Inc. (PFE)

- NYSE
  • Nov. 21, 2011, 6:44 AM
    UnitedHealth (UNH) plans to charge a lower co-pay for Pfizer's (PFE) cholesterol-fighting pill Lipitor than it does for generic versions. The action takes advantage of a strategic price reduction initiative offered by Pfizer to insurers and pharmacy benefit management companies for 180 days aimed at improving its market share in advance of Lipitor's patent expiration.
    | Comment!
  • Nov. 17, 2011, 7:20 AM
    Pfizer (PFE) announces the European Commission has approved its Vyndaqel treatment for a rare, progressive and fatal neurodegenerative disease. The company says it's working with health authorities across the EU with a goal to launch the treatment into markets by early 2012. Shares -0.5% premarket.
    | Comment!
  • Nov. 17, 2011, 4:19 AM
    An FDA advisory panel has backed extending to the over 50s the use of Pfizer's (PFE) Prevnar 13 vaccine for helping to prevent pneumonia. Should it win FDA approval, which is contingent on an ongoing trial, the drug could add almost $2B in sales in 2015. It's already approved for young children.
    | Comment!
  • Nov. 16, 2011, 2:59 PM
    A Credit Suisse list of 20 stocks that reward investors with greater dividend payments than most bonds: KO, MCD, GIS, PEP, PG, JNJ, ABT, KMB, ED, PFE, BMY, SO, MRK, PM, PGN, DUK, LLY, VZ, T, MO. Average yield: 4.2%. Average YTD returns on the underlying stock: 13.3%.
    | 1 Comment
  • Nov. 14, 2011, 1:24 PM
    Leerink Swank analyst Seamus Fernandez downgrades Pfizer (PFE -1.1%) to Market Perform from Outperform - seeing few catalysts in line to help lift sales and EPS estimates after factoring in the company's current drug pipeline. He keeps a mild price target of $21 in place - repping a potential cooling for shares after running up 13% YTD.
    | Comment!
  • Nov. 14, 2011, 3:56 AM
    Apixaban, an anticoagulant from Pfizer (PFE) and Bristol-Myers Squibb (BMY), isn’t safer or more effective than the standard treatment, Sanofi’s Lovenox (SN), at preventing blood clots in the legs and lungs of patients after hospitalization, a Phase III trial has shown. (PR)
    | Comment!
  • Nov. 8, 2011, 11:55 AM
    Maybe investors have had their fill of David Einhorn’s worries about Green Mountain Coffee (GMCR +1.2%), as shares rise despite the hedge funder's latest bearish pronouncements of many (last month). In addition to selling out of PFE and BP during Q3, Einhorn's firm initiated new positions in CBS, GM and MRVL.
    | 2 Comments
  • Nov. 8, 2011, 11:11 AM
    David Einhorn says he has sold out of his position in Pfizer (PFE), citing concerns about drug reimbursement cuts and government investigations into the company's marketing practices. Einhorn also claims to have exited his BP position, partly due to fears of falling energy prices. (previously)
    | 2 Comments
  • Nov. 1, 2011, 10:45 AM
    More on Pfizer's (PFE -0.8%) Q3: In addition to EPS and revenue beats, the company raised full-year EPS guidance and boosted its share repurchase program. But the loss of patent protection on major drugs is taking a bite out of results, as earnings in its primary care division fell 7% Y/Y. Pfizer will lose patent protection on its blockbuster heart drug Lipitor this month.
    | Comment!
  • Nov. 1, 2011, 7:47 AM
    Pfizer (PFE): Q3 EPS of $0.62 beats by $0.07. Revenue of $17.2B (+7.5% Y/Y) beats by $0.8B.(PR)
    | Comment!
  • Nov. 1, 2011, 12:05 AM
    Notable earnings before Tuesday's open: ABC, ADM, AMT, BHI, EMR, ETR, EXPD, FE, FIS, HCA, MAC, MHP, NXPI, OHI, OSK, PCS, PFE, PNW, RDC, SIRI, THC, TRI, VLO, VSH, WPI
    | Comment!
  • Oct. 27, 2011, 7:13 AM
    Pfizer (PFE) receives EU approval to extend the use of its Prevenar 13 drug to adults 50 years and older for the prevention of invasive pneumococcal disease. Shares +1.2% premarket.
    | Comment!
  • Oct. 24, 2011, 4:23 AM
    China Mengniu Dairy (CIADF.PK), the country's largest dairy company, may bid for Pfizer's (PFE) infant-nutrition business, reports say. However, with the unit expected to fetch up to $10.5B, the acquisition may be hard to pull off for Mengniu, as its market cap is just HK$43.7B ($5.6B).
    | 1 Comment
  • Oct. 19, 2011, 11:38 AM
    Some of the world's biggest and best-known stocks have lain comatose for years, many of them leaders in a host of industries - WMT, CSCO, PFE, INTC, GE, MSFT, AMGN, F, TWX, MDT - and among the most widely held stocks in America. More than $2T is locked up in blue chips that have gone absolutely nowhere or down for a decade.
    | 4 Comments
  • Oct. 17, 2011, 8:01 AM
    Acura Pharmaceuticals (ACUR) provides an update on its opioid product licensed to Pfizer (PFE), saying Pfizer is executing a commercialization plan for Oxecta tablets in the U.S. The company will receive royalties ranging from 5% to 25% on the sale of the respiratory treatment one year after the anniversary of the first sale.
    | Comment!
  • Oct. 11, 2011, 3:22 PM
    Pfizer (PFE -0.6%) - staring a loss of its monopoly for Lipitor right in the face - attempts to block rival Merck's (MRK -1.1%) introduction of a generic version of the cholesterol-lowering treatment for five years with a strategic federal lawsuit. The bigger question: How long can Pfizer continue to "play defense" in the courtroom to protect its sales as patent expirations start to kick in?
    | 3 Comments
Visit Seeking Alpha's
PFE vs. ETF Alternatives
Company Description
Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare.